AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02864524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manipulative and Massage Therapy
Study NCT02864524 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Study NCT05819437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balneotherapy program
Description: Whirlpool bath, bath with immersion showers, poultice application and underwater massage.~The baths were performed in an individual tub in ten-minute sessions. The temperature was set specifically for each patient, on average from 34 to 38°C. These were baths with jets and air diffusion.~The mud was applied as a poultice to the 2 knees and if necessary (duration of application: 10 minutes).~The massages were carried out by qualified physiotherapists under an affusion ramp of thermal water at 38°C for 10 minutes.~The water used is a mixed sulphated Natural Mineral Water, collected by drilling the capuchins at a depth of 975 m. The temperature of the water at the outlet of the borehole is 41.8°C and is lowered to 35°C.
Study NCT00973050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: 50 mg Tablet
Study NCT00974766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: Prednisolone 0.75 mg/kg/day for 6 weeks; then 0.5 mg/kg/day for 6 weeks. Then taper by 5 mg every 6 weeks and discontinue
Study NCT00973050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Casodex®
Description: 50 mg Tabelt
Study NCT00101725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crofelemer
Study NCT00101725 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: crofelemer
Study NCT04516811 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma (CCP) plus standard of care (SOC)
Description: A single unit of approximately 200-250 mL of CCP that contains anti-SARS-CoV-2 collected by plasmapheresis from a volunteer who recovered from COVID19 with SOC as determined by local practice and guidelines.
Study NCT04516811 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care (SOC) plus placebo
Description: A single unit of 200 mL normal saline with SOC as determined by local practice and guidelines
Study NCT04543344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recifercept
Description: recifercept powder for solution for injection
Study NCT04543344 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: solution for injection
Study NCT03422978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Single dose dexmedetomidine administered over 60 seconds post-induction.
Study NCT03422978 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Description: Single dose normal saline administered over 60 seconds post-induction.
Study NCT02396030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate 50% - 1g/h
Description: Patients will receive after the loading dose os magnesium sulfate, the maintenance dose of 1g/hour of intravenous of magnesium sulfate for 24 hours after loading dose
Study NCT02396030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 50% - 2g/h
Description: Patients will receive after the loading dose os magnesium sulfate, the maintenance dose of 1g/hour of intravenous of magnesium sulfate for 24 hours after loading dose
Study NCT04599452 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic NK cell regimen group
Description: 10 patients with recurrent refractory elderly AML were treated with allogeneic NK cell regimen.~Allogeneic NK cell regimen ×3 cycle; Cyclophosphamide 300mg/m2.d d1to 3; G-CSF 150ug bid d4-11; Azacitidine 75mg/m2 d5-11; Allogeneic NK cell 10-30×10\^6/kg d13，d15.
Study NCT04655313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ-151 cream 0.3%
Description: ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks
Study NCT01330355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besivance
Description: Besifloxacin hydrochloride 0.6% ophthalmic suspension, one drop instilled into infected eye, three times daily (TID) for 7 days
Study NCT01330355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gatifloxacin
Description: Gatifloxacin 0.3% ophthalmic solution one drop instilled into infected eye, TID for 7 days
Study NCT01528124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3025876
Description: Given as a subcutaneous injection
Study NCT01528124 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given as a subcutaneous injection
Study NCT03836664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol
Description: Timolol is a clear solution supplied in a plastic ophthalmic dispenser.
Study NCT03836664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is normal saline solution that will be supplied in container matched to Timolol container.
Study NCT00743405 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GSK1034702
Description: Oral or liquid
Study NCT00743405 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: To match GSK1034702
Study NCT01916967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine
Description: Desloratadine 5 mg tablets, given orally, once daily in the evening for 2 weeks
Study NCT03393910 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Pelvic Exam
Description: The pelvic exam will be completed in the following order: external, speculum, bimanual exam in the standard group. In the Experimental group the pelvic exam will be done with external xam, bimanual exam then speculum exam.
Study NCT01924481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Caffeine
Study NCT01924481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Caffeine
Study NCT01924481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low caffeine
Study NCT01924481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High theobromine
Study NCT01924481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low theobromine
Study NCT01924481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: No theobromine
Study NCT01916967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets, given orally, once daily in the evening for 2 weeks
Study NCT01916967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, given orally, once daily in the evening for 2 weeks
Study NCT01309308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sweeping the membranes
Description: The cervical length will be measured and the patient will be examined to determine the Bishop score. Later the the membranes will be swept.
Study NCT01309308 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No sweeping group
Description: Cervical length will be measured by transvaginal USG and the patient will be examined to determine the Bishop score.
Study NCT04167722 — intervention group
Intervention type: PROCEDURE
Intervention: Robotic Radical Prostatectomy
Description: Routine NHS Radical Prostatectomy
Study NCT02702063 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: passive leg raising test
Description: Patients undergoing routine echocardiography are exposed to a passive leg raising test. Change in SV will be measured by TTE and compared to changes in SV measured by EC.
Study NCT00998959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction and Psychoeducation
Description: Participants will receive six individual weekly 50-minute sessions of mindfulness based stress reduction (MBSR) as well as problem solving therapy (PST. PST is a type of therapy that focuses on psychosocial problems and using your skills and resources to function better. MBSR uses exercises in mindfulness to reduce stress.
Study NCT00998959 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychoeducation
Description: Participants will receive six individual weekly 50-minute sessions of psychoeducation. Psychoeducation consists of education on depression, its symptoms, its treatment, and recovery.
Study NCT00004228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IV
Study NCT00004228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT02702063 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: right heart catheterisation
Description: CO in patients undergoing routine right heart catheterisation will be measured and compared between 3 methodologies: right heart catheterisation, TTE and EC
Study NCT02702063 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: TTE vs. EC + calibration group
Description: Patients will undergo routine echocardiography. CO and SV will be measured by TTE and compared to measurements obtained from simultaneous EC-measurements.
Study NCT03024437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be given intravenously every 3 weeks at 1200 mg.
Study NCT03024437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be given intravenously every 3 weeks at 15 mg/kg.
Study NCT03024437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Entinostat will be given orally every 7 days at 1, 3, or 5 mg depending upon phase. In Phase I, dose levels will be tested in up to 3 cohorts starting at 1 mg. In Phase II, the dose will be the recommended phase II dose that was determined during Phase I (i.e., 1, 3, or 5 mg).
Study NCT00004228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT06275581 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ketac Universal Aplicap Glass Ionomer Restorative (3M) (test group)
Description: Ketac Universal Aplicap Glass Ionomer Restorative (test group) was applied in one cavity of the patient, randomized allocated, in a stress bearing Class II restoration when the isthmus was less than half of the intercuspal distance and with at least one occlusal contact on enamel of the restored tooth. This material does not require a cavity conditioning step prior to restoration placement.
Study NCT06275581 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ketac Molar Quick Aplicap Glass Ionomer Restorative (control group)
Description: Ketac Molar Quick Aplicap Glass Ionomer Restorative (control group) was applied in the other cavity of the patient,randomized allocated, in a stress bearing Class II restoration when the isthmus was less than half of the intercuspal distance and with at least one occlusal contact on enamel of the restored tooth.
Study NCT02374515 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EndoCuff-assisted colonoscopy
Description: Adenoma detection rate
Study NCT02374515 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Colonoscopy
Study NCT04223232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-MD1003
Description: single oral dose of 100mg \[14C\]-MD1003
Study NCT02567201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrophysiological evaluation
Description: electrophysiological assessment (experience 1 : passive ; experience 2 : active versus passive ; experience 3 : active, with feedback) Experience 1, 2, 3 : one session maximum by experience
Study NCT02567201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrophysiological evaluation of patients
Description: electrophysiological assessment (experience 1 : passive ; experience 2 : active versus passive ; experience 3 : active, with feedback) Experience 1 : maximum one session by sensory modality of stimulation (auditory, tactile, or visual) Experience 2 : maximum one session by sensory modality of stimulation (auditory, tactile, or visual) Experience 3 : Stimulation = auditory or visual ; possibility of several sessions if the patient is tired.
Study NCT04061980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO
Study NCT04061980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Given PO
Study NCT04061980 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT06138093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sealing device
Description: Intratracheal tracheostomy sealing
Study NCT06138093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No device
Description: Open tracheostomy wound
Study NCT03860142 — intervention group
Intervention type: BEHAVIORAL
Intervention: Archet scale
Description: Parents will be asked to answer questions about their child's nutrition by using a new scale : Archet scale
Study NCT03775161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-LAP™ System
Description: Delivery of the V-LAP™ implant via a catheter-based approach in a trans-septal puncture procedure, deploying it in the inter-atrial septum.
Study NCT02639156 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AYMES LONDON
Description: AYMES LONDON is a powder, designed to be mixed with 75ml whole milk to make a dessert style ONS. When made-up, AYMES LONDON provides 303kcal (2.2kcal/ml) and 11.2g protein. It is not designed to be used as a sole source of nutrition. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision.
Study NCT00606827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate
Description: Patients in the sodium bicarbonate group (154 mEq/L) received 3 ml/kg for 1 hour before contrast medium, followed by an infusion of 1 ml/kg/h for 6 hours after the procedure
Study NCT00606827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic Saline
Description: Patients assigned to the isotonic saline group received 1 ml/kg/h 0.9% sodium chloride for 12 hours before and after the procedure
Study NCT02355496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Displaying medicare fee data
Description: Using the computerized order entry system to make medicare fee data for a randomly selected inpatient laboratory tests transparent to providers at the time of order entry.
Study NCT00586846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 120 mg/m\^2
Study NCT00586846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 75mg/m\^2
Study NCT00586846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 12g/m\^2
Study NCT05067959 — intervention group
Intervention type: BIOLOGICAL
Intervention: Covid-19 vaccine
Description: blood tests and questioners before 1st vaccine, 3 weeks before 2nd vaccine, 4 weeks after 2nd vaccine, 6 months after 1st vaccine, and 12 months after 2nd vaccine
Study NCT02862054 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: splenectomy
Study NCT03318120 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training
Description: Participants will perform required resistance training exercises at regular intervals for a period of up to 3 years. They will be tested at a baseline visit, then every 6 months for a total of at least 5 visits. During these visits, they will be asked to complete the following: questionnaires about quality of life and depression, tests to measure strength and motor function, tests to measure cognition, an orientation session to learn a precision griping task, structural and functional MRI scans of the brain, measurement of brain waves using a non-invasive technique called electroencephalography (EEG) and muscle activity using electromyography (EMG), measurement of brain function with TMS, pregnancy test (if applicable).
Study NCT00647413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: bio-chemical feedback and expert system intervention ETS
Description: Urinary cotinien will be measured using urine collected from the infants diaper. It will be analysed and the result will be explained to the participant in a written letter approximately 2 weeks after the intervention.~The intervention will also be a counselling session about the consequences of ETS to the infant. The counselling will be guided by the principles of motivational intervieweing and an expert system letter tailored to the data assessed will be send to the participants
Study NCT03353272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Engagement Education and Restructuring of Cognitions
Description: This protocol, informed by principles of CBT, involves three components: 1) engagement, 2) education and 3) cognitive restructuring and behavioral activation. A health coach who is responsible for engaging patients, educating them about pain modulatory mechanisms, and reinforcing cognitive and behavioral coping skills, will deliver the PEERC protocol.
Study NCT00582790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL2
Description: Interleukin-2 will be given at a starting dose of 7 MU/m2/day by subcutaneous injection days 1-5, on weeks 1 through 3, in four week (28 days) cycles.
Study NCT00582790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic acid will be given on day 1 intravenously over 15 or 30 minutes starting at 400mcg. If no significant increase in gamma delta-T cell augmentation is seen, the dose of zoledronic acid will be increased in the subsequent cycle up to a maximum dose of 3mg.
Study NCT03570255 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RD SET Neo SpO2
Description: All subjects are enrolled in the experimental group and receive the RD SET Neo SpO2 sensor.
Study NCT00790062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: See arms
Study NCT00790062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: See arms
Study NCT00874796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9450
Description: Taken as one capsule by mouth once daily
Study NCT00004228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV
Study NCT00874796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taken as one placebo capsule (matching in appearance to GS-9450 capsules) by mouth once daily
Study NCT01445756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: During the procedure (placement of the IUD), 1ml of gel will be applied to the anterior lip of the cervix. After 1 minute of waiting, a tenaculum will be placed to steady the cervix. The catheter will be introduced into the cervical canal, past the external os and 1-1.5ml of gel will be placed into the canal. After another minute, the IUD will be placed in the standard fashion.
Study NCT01445756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo; no topical lidocaine administered
Study NCT02636413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gaxilose
Description: After gaxilose administration, urine collection, cuantification (firstly from 0 to 4 hours, and total urine from 0 to 5 hours), and xilose cuantification afterwards.
Study NCT02173184 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gynevac
Description: 1 IM injection of Gynevac per week, for 4 weeks (five injections in total). Vaccination can take place in no less than 7 days intervals (+3 days).
Study NCT02173184 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 IM injection of Placebo per week, for 4 weeks (five injections in total). Vaccination can take place in no less than 7 days intervals (+3 days).
Study NCT00486174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylene blue
Description: 2.0 mg/kg of Methylene Blue administered every 6 hours (as required) for up to 48 hours.
Study NCT04082559 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Arm 1- Antibiotics treatment
Description: Patients with active disease will be randomized and will receive a prescription antibiotic regimens
Study NCT04082559 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Arm 2- Antibiotics treatment
Description: Patients with active disease will be randomized and will receive a prescription antibiotic regimens
Study NCT04082559 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Arm 1- Combination therapy (Antibiotics + diet)
Description: Patients with active disease receiving a prescription for the antibiotic regimen defined as favorable in the antibiotics according to aim 1 , and randomized into one of two dietary interventions: Mediterranean diet (MED) or the specific carbohydrate diet (SCD).
Study NCT02636413 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lactose
Description: After lactose administration, expired hydrogen measurement at pre-specified intervals.
Study NCT01781338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Induction therapy
Description: The intervention is dependent on the respective sub-protocol and can include either endocrine therapy, neoadjuvant chemotherapy or targeted therapy.
Study NCT02638298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevana Dressing
Description: negative pressure wound therapy (NPWT) dressing